This trial evaluates the addition of rituximab to standard of care in the treatment of
antibody-mediated rejection in kidney transplant patients. The trial will involve adults and
children. Half of participants will receive standard of care (methylprednisolone, intravenous
immunoglobulin and plasma exchange), while the other half will receive standard of care and
rituximab.
Phase:
Phase 3
Details
Lead Sponsor:
Imperial College London
Collaborators:
Cambridge Clinical Trials Unit Cambridge University Hospitals NHS Foundation Trust Kidney Cancer UK National Institute for Health Research, United Kingdom